Nothing said here yet.
to join the conversation.
| Palumbo Joseph MChief Medical Officer | Buy | 4,843 | $10.5K | Fri, Aug 28 |
| KIM JOANNE WENDYChief Financial Officer | Buy | 2,500 | $5.5K | Fri, Aug 28 |
| Chappell Amy SuzonDirector | Buy | 727 | $1.6K | Fri, Aug 28 |
| DO CUONG VPresident & CEO | Buy | 15,210 | $31.6K | Thu, Aug 27 |
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at…
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Proactive's Stephen Gunnion after the company presented findings from its Long COVID and Parkinson’s disease trials at the American Neurological Association’s Annual Meeting in San Diego.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson’s disease, at the American Neurological Association’s annual meeting in San Diego.
Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p.
ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp.
BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could strengthen the case for targeting inflammation and insulin…
BioVie (NASDAQ:BIVI) shares fell nearly 9. 7% in premarket trading after the company reported results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms associated with Long COVID.